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BACKGROUND:Advance care planning is widely advocat-
ed to improve outcomes in end-of-life care for patients
suffering fromheart failure. But until now, there has been
no systematic evaluation of the impact of advance care
planning (ACP) on clinical outcomes. Our aim was to
determine the effect of ACP in heart failure through a
meta-analysis of randomized controlled trials (RCTs).
METHODS:We searchedCINAHL, Cochrane Central Reg-
ister of Controlled Trials, Database of Systematic Reviews,
Embase, ERIC, Ovid MEDLINE, Science Citation Index
and PsycINFO (inception to July 2018). We selected RCTs
including adult patients with heart failure treated in a
hospital, hospice or community setting. Three reviewers
independently screened studies, extracted data, assessed
the risk of bias (Cochrane risk of bias tool) and evaluated
the quality of evidence (GRADE tool) and analysed inter-
ventions according to the Template for Intervention De-
scription and Replication (TIDieR). We calculated stan-
dardized mean differences (SMD) in random effects
models for pooled effects using the generic inverse vari-
ance method.
RESULTS: Fourteen RCTs including 2924 participants
met all of the inclusion criteria. There was a moderate
effect in favour of ACP for quality of life (SMD, 0.38; 95%
CI [0.09 to 0.68]), patients’ satisfaction with end-of-life
care (SMD, 0.39; 95% CI [0.14 to 0.64]) and the quality
of end-of-life communication (SMD, 0.29; 95% CI [0.17 to
0.42]) for patients suffering from heart failure. ACP
seemed most effective if it was introduced at significant
milestones in a patient’s disease trajectory, included fam-
ily members, involved follow-up appointments and con-
sidered ethnic preferences. Several sensitivity analyses
confirmed the statistically significant direction of effect.
Heterogeneity was mainly due to different study settings,
length of follow-up periods and compositions of ACP.
CONCLUSIONS: ACP improved quality of life, patient sat-
isfaction with end-of-life care and the quality of end-of-life
communication for patients suffering from heart failure
and could be most effective when the right timing, follow-
up and involvement of important others was considered.
KEY WORDS: heart failure; palliative care; advance care planning; effect;
outcomes; systematic review; meta-analysis.
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BACKGROUND
Regardless of therapeutic advances, heart failure remains an
unpredictable, progressive and ultimately fatal long-term con-
dition.1, 2 Existing therapies delay, but generally tend not to
reverse disease progression.3 Consequently, the prevalence of
symptomatic heart failure has increased, including a prolon-
gation of the refractory phase of the disease.4 An ageing
population, a rising prevalence and new life-prolonging treat-
ment approaches mean that over 5% of patients suffering from
heart failure have developed treatment refractory symptoms.5
There is widespread recognition that these patients merit sup-
port from specialist supportive and palliative care services.6–10
Advance care planning (ACP) is widely advocated to im-
prove quality of life and patient satisfaction with end-of-life care
in heart failure and a reduction of stress and depression in
surviving relatives.5, 7, 11, 12 ACP is defined as a voluntary
process of discussion between healthcare professionals, patients,
family and important others to identify patient’s preferences if
the patient may lack the competence to make such decisions in
the future.13, 14 ACP can be a chance for patients to describe
what they want to happen and what they do not want to happen
in the future. For example, ACP supports patients by clarifying
their resuscitation preferences in case of a cardiac arrest, whether
or not or under what circumstances to disable an implantable
cardioverter-defibrillator (ICD), choosing a healthcare proxy,
deciding on their preferred place of care or making decisions
on artificial hydration.13 ACP can take the shape of a structured
discussion or result in the documentation of care preferences in
medical records that are regularly reviewed and updated. The
context of ACP can be a nurse or consultant-led heart failure
outpatient clinic, during inpatient care, or in the course of an
appointment with a primary care clinician.
While the use of ACP is promoted to provide better clinical
outcomes, its effectiveness to achieve that aim has not been
systematically assessed.15 The majority of systematic reviews
on ACP are concerned with the effect of interventions that
promote the implementation of ACP and assess outcomes like
the rate of ACP conversations or the completion of ACP
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documents.16–21 The systematic literature reviews that inves-
tigate the impact of ACP on end-of-life care outcomes com-
bine qualitative and quantitative studies, do not conduct a
meta-analysis and do not focus on the effect of ACP on heart
failure.22–27 The aim of this study was to undertake a system-
atic review and meta-analysis of RCTs to determine whether
end-of-life care which included ACP resulted in improved
outcomes for patients suffering from heart failure compared
to end-of-life care which did not incorporate ACP. Our hy-
pothesis was that ACP improved clinical outcomes for patients
suffering from heart failure. Our main research question was
“What is the effect of ACP on clinical outcomes for patients
suffering from heart failure?”
The objectives were as follows:
& To determine the effect of advance care planning on the
quality of life of patients suffering from heart failure,
their satisfaction with end-of-life care through random
effects meta-analyses
& To conduct sensitivity analyses and investigate causes of
clinical heterogeneity
& To explore characteristics of advance care planning
interventions that are associated with high and low effect
sizes
METHODS
We conducted this review in accordance with the Preferred
Reporting Items for systematic reviews and meta-analysis
(PRISMA-P),28 the Cochrane Collaboration reporting items
for systematic reviews and meta-analysis29 and the Grading of
Recommendation Assessment, Development, and Evaluation
(GRADE) for the quality of evidence in selected trials.30
Intervention impact was reported based on CONSORT guide-
lines.31 Additional File (AF) 1 shows the review protocol.
Study Selection
We included only randomized controlled trials (RCTs) and
cluster randomized controlled trials (cRCTs). No restrictions
were placed on the healthcare setting, context or healthcare
professional involved. Patients were eligible if they suffered
from heart failure defined as a complex syndrome in which the
ability of the heart to maintain the circulation of blood is
impaired as a result of a structural or functional impairment
of ventricular filling or ejection.5 Symptoms were classified
according to severity using the New York Heart Association
(NYHA) functional classification as found in medical records
or by a clinician’s diagnosis.32 Patients were seen in primary or
secondary care, living in the community or nursing homes.We
did exclude studies involving people under the age of 18 years
and suffering from congenital heart disease.33
As defined in policy documents and by experts, we includ-
ed all types of ACP interventions that provided a coordinated
and comprehensive approach of care for patients early, during
or towards the end of suffering from heart failure.33–35 Authors
had to state explicitly ACP intentions or this had to be evident
in the composition of the intervention of the study. Interven-
tions that only dealt with do-not-attempt cardio-pulmonary-
resuscitation were excluded from the study because they on
their own did not represent the complexity of ACP.36
We followed the recommendation of the European Associ-
ation for Palliative Care for the selection of outcome mea-
sures37 including patient-reported outcome measures that had
been validated with heart failure patients requiring palliative
care.38 Therefore, we selected a priori as our primary outcome
quality of life. As secondary outcomes, we chose patient
satisfaction with end-of-life care and the quality of end-of-
life communication between clinician and patient. Outcomes
had to be measured through instruments that had psychometric
properties.
Data Sources and Searches
Together with a specialist health science librarian (NR), we used
filters to reliably identify RCTs and searched the following data
bases from their inception until 13 July 2018: CINAHL,
Cochrane Central Register of Controlled Trials, Cochrane Da-
tabase of Systematic Reviews, Database of Abstracts of Re-
views of Effects, Embase, ERIC, Ovid MEDLINE (SP), Other
Non-Indexed Citations and Ovid MEDLINE(R), Science Cita-
tion Index, Social Science Citation Index & Conference Pro-
ceedings and PsycINFO. A MEDLINE search strategy is pre-
sented in AF 2. We checked the reference lists of 11 relevant
reviews16–25, 39 and all potential cross references. We contacted
authors of main trials and experts in the field who were known
to conduct research for additional papers or to provide missing
or unpublished study data.
Data Extraction and Quality Assessment
Titles and abstracts were independently screened against inclu-
sion criteria by two reviewers (MS, IO). Disagreements were
resolved by discussion or referred for arbitration to a third
reviewer (RP). Full texts of screened papers were assessed for
inclusion criteria and study quality. We pilot tested eligibility
criteria and included a flow diagram of study selection and
reasons for exclusion to conform to the PRIMSA statement.
We assessed the overall quality of the trials’ methods by
using the GRADE system Version 3.6.1.40 A GRADE profile
was created for each pooled estimate, for each outcome and for
single trials comparing ACP with standard care for each end-
of-life outcome. Two authors (MS, IO) independently extract-
ed data from papers and documented findings. AF 3 gives an
example of a data extraction form.
Data Synthesis and Analysis
We performed quantitative meta-analysis with RevMan 5.3.541
using random effects models. For individual studies with
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continuous outcomes measured by a variety of scale instruments,
we calculated standardized mean differences (SMDs) with 95%
confidence intervals (CI) between the intervention and control
group as recommend by Cochrane.29 The effect of SMDs was
interpreted as follows: < 0.2 = small effect; between 0.2 and 0.5
moderate effect; 0.5 or higher = large effect.29 We re-expressed
SMDs to odds ratios [log(OR) = SMD × pi / sqrt3] to aid clinical
interpretation as recommended by the Cochrane Handbook.29
We did not adjust sample sizes to account for clustering in the
included cRCT42 as this study reported adjusted effect estimates,
which took the intra-class coefficient found into consideration.
We used a generic inverse variance approach and random effects
meta-analysis to include the estimate into the meta-analysis.
Whenmultiple time points were reported, we used the one closest
to 3 months post-intervention based on research practice in
palliative care43 and the premise that it would require a reason-
able length of time for ACP to take effect.
We assessed heterogeneity using the I2 statistic stating the
percentage of variability in effect estimates that is due to hetero-
geneity rather than to chance.44 Thresholds for the interpretation
of heterogeneity were based on Cochrane guidance29 as follows:
0%=no heterogeneity; > 0 to 40%:might not be important; 30 to
60%: moderate heterogeneity; 50 to 90%: substantial heteroge-
neity; 75 to 100%: considerable heterogeneity. We investigated
clinical heterogeneity by pre-specified subgroup analyses for
each outcome stratified for patient population, length of follow-
up periods and study setting. We compared interventions that
included only ACP and interventions that included ACP as part
of a palliative care programme.We analysed the characteristics of
ACP interventions that resulted in either high or low effect sizes
for each outcome and explored their content, timing and frequen-
cy and context of the intervention according to the Template for
Intervention Description and Replication (TIDieR).45
We assessed publication bias by investigating the funnel
plot symmetry and performing Egger’s test46 with STATA
version 14.47 Two reviewers (MS, IO) independently assessed
the risk of bias using the Cochrane Collaboration’s tool for risk
of bias domains.48
RESULTS
Of 9130 articles screened, we reviewed the full text of 85
studies. Fourteen studies (13 RCTs, one cRCTs) met all of the
inclusion criteria for the quantitative analysis. Figure 1 shows
the PRISMA flow diagram. A detailed description of each trial
is provided in Table 1. We included 14 studies in the meta-
analysis involving 2924 unique participants. We excluded 71
studies with reasons provided in AF 4 “Characteristics of
Excluded Studies.”
Characteristics of Included Studies
Ten of the 14 studies were conducted in the USA, one in the
UK,53, one in Australia,54 one in Sweden50 and one in Hong
Kong.61 The median sample size was 209 people (range 27 to
517 participants). The median age of participants was 65.85
(age range 58.1–84.5 years). 40.83% (n = 1194) of the total
study population were female.
A summary of a risk of bias table and a risk of bias ratings
for each study and each trial arm is included in AF 5. Alloca-
tion concealment (selection bias) was unclear in seven studies
as authors did not describe methods of concealment. Blinding
of participants was not possible in seven trials because of the
nature of the interventions. One study had a high risk of
detection bias since outcome assessors were aware of the
participants’ allocation to the intervention group.56
Effects of ACP on Outcomes for Heart Failure
AF 6 shows the GRADE quality ratings for each outcome. The
mean score for the overall quality of evidence across all
studies was low to moderate. This was mainly due to the fact
that many participants could not be blinded to the nature of the
intervention introducing a high risk of performance bias.
Meta-analysis on ACP and Quality of Life
Quality of life (QOL) was determined in seven studies (724
patients) (Fig. 2). ACP was associated with a statistically
significant improvement for QOL (SMD, 0.38; 95% CI
[0.09 to 0.66], p < 0.009). The median follow-up duration
was 12 weeks. Egger’s test did not show any evidence (p =
0.406) of a small study effect on publication bias (AF 7).
Meta-analysis on ACP and Patient Satisfaction
Patient satisfaction with end-of-life care was assessed in
four studies (1290 patients). ACP was associated with
(Fig. 3) a statistically significant effect (SMD, 0.39;
95% CI [0.14 to 0.64]; p = 0.003). The median
follow-up duration was 14.4 weeks. Egger’s test did
not show any evidence (p = 0.584) of a small study
effect on publication bias (AF 7).
Meta-analysis on ACP and Quality of End-of-
Life Communication
Four studies measured the effect of ACP on the quality of end-
of-life communication (995 patients). ACP was associated
with statistically significant improvement (Fig. 4) for the
quality of end-of-life communication (SMD, 0.29; 95% CI
[0.17 to 0.42]; p < 0.001). The median follow-up duration was
7.25 weeks. Egger’s test of the 4 RCTs did not show any
evidence (p = 0.095) of a small study effect on publication bias
(AF 7).
To aid the clinical interpretation of the results, we re-
expressed estimated SMDs for all outcomes as odds
ratios according to Cochrane guidelines (AF 8).29 ACP
improved the quality of life for heart failure patients by
approximately 93%, patient satisfaction with end-of-life
care by about 96% and the quality of end-of-life com-
munication by around 52%.
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Characteristics of ACP Interventions with High
and Low Effect Sizes
Table 2 summarizes the characteristics of ACP interven-
tions with the highest and lowest effect sizes by out-
come. Generally, ACP interventions that included multi-
ple components, educated patients, involved family
members, offered follow-up and considered ethnic pref-
erences were more effective than single component in-
terventions that did not educate patients, did not involve
family members and did not offer follow-up.
Sensitivity Analyses and Heterogeneity
Several sensitivity analyses (AF 9) including studies re-
stricted to ACP only (SMD, 0.35; 95% CI [− 0.10 to
0.81]) versus ACP plus palliative care programme (SMD,
0.32; 95% CI [0.16 to 0.48]), US-based studies (SMD,
0.37; 95% CI [− 0.05 to 0.79]) versus not US-based studies
(SMD, 0.39; 95% CI [− 0.04 to 0.83]), and trials at low
risk of bias (SMD, 0.34; 95% CI [0.03 to 0.65]) confirmed
the consistency of the results of the primary analyses.
To investigate possible causes of heterogeneity, additional
sensitivity analyses were performed by stratifying outcomes for
patient populations, study settings and length of follow-up pe-
riods. No heterogeneity was detected for the hospital setting for
quality of life, for the quality of end-of-life communication and
for heart failure and other terminally ill patients for the outcome
quality of end-of-life communication. Levels of heterogeneity
seemed lower for shorter follow-up periods (1 to 4 weeks) than
for longer follow-up durations (up to 12 or 24 weeks). Quality of
life and patient satisfaction with end-of-life care showed higher
levels of heterogeneity than quality of end-of-life communica-
tion. A summary of causes of heterogeneity for each outcome
and subgroup is presented in Table 3. These differences are
explored in more detail under the “Discussion” section.
DISCUSSION
Principal Findings
This literature review was the first systematic evaluation of the
evidence base for the effect of ACP on end-of-life care outcomes
Figure 1 PRISMA flow diagram
Schichtel et al.: The Effect of Advance Care Planning on Heart Failure: a Systematic Review and Meta-analysisJGIM 877
in heart failure. The results of the meta-analyses from 14 RCTs
including 2924 participants indicated that ACP improved.
& Quality of life (SMD, 0.38; 95% CI [0.09 to 0.66])
& Patient satisfaction with end-of-life care (SMD, 0.39;
95% CI [0.14 to 0.64])
& Quality of end-of-life communication (SMD, 0.29; 95%
CI [0.17 to 0.42]) in heart failure compared to usual care
Several sensitivity and subgroup analyses confirmed the
direction of the effect. ACP alone compared to ACP as part
of a palliative care programme might be equivalent in its
effectiveness. ACP that included not only patients but also
family members, offered follow-up occasions and considered
ethnic preferences was more effective than ACP that did not
cover these criteria.
Comparison with Other Reviews
At the time of writing, this review was the first to have
analysed the effect of ACP on outcomes in heart failure
in a meta-analysis with a consideration of heterogeneity
and characteristics of intervention effectiveness. Several
reviews had investigated the effectiveness of interven-
tions to implement ACP but did not investigate the
impact of ACP on heart failure.17–21, 23–26, 36 Some of
these reviews conflated an analysis of the impact of
ACP on end-of-life outcomes with the effect of inter-
ventions to promote the implementation of ACP.26 Data
on the actual impact of ACP on end-of-life outcomes
was only presented descriptively and missing for heart
failure.26, 36
Table 1 Summary of Included Studies
Study
(years)
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Strengths and Limitations
The strength of this review and meta-analyses consisted of the
use of a robust search strategy, assessing the overall quality of
the evidence with the GRADE system, rating risks of biases
with the Cochrane risk of bias evaluation tool, statistically
pooling data for each outcome, performing sensitivity analy-
ses and exploring causes of heterogeneity and intervention
effectiveness. Furthermore, we used random effects models
and SMDs to account for variations in types of interventions
and outcomes measures across studies.
The heterogeneity in studies was mainly due to different
study populations combining heart failure patients with pa-
tients suffering from other life-limiting illnesses, different
study settings, follow-up periods and a lack of standardization
of using outcomes measures. The median age of participants
was below the median age of people dying from heart failure
in the general population. The median follow-up periods for
clinical outcomes were comparatively short. It appears unclear
whether the positive effect of ACP might mitigate over time.
The majority of studies originated from the US but a sensitiv-
ity analysis comparing effect sizes of US-based studies with
studies from other countries did not show a favourable effect
dependent of the health care setting.
Causes of Clinical Heterogeneity
Heterogeneity is to be expected when aggregating evidence on
the effect of complex interventions like ACP.62 ACP in itself
tends to consist of multiple components and is implemented
differently and in different settings.63 For example, the timing
of offering ACP as an intervention in relation to the patient’s
Figure 2 Effect of ACP on quality of life.
Figure 3 Effect of ACP on patient satisfaction.
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disease trajectory varied in included studies. While most pa-
tients in the meta-analysis suffered from heart failure class III
or IVof the New York Heart Association, ACP was initiated at
different time points: during an admission to hospital,58 after a
recent hospitalization,55 after a deterioration in the patient’s
health status52 or before a routine clinic appointment with a
cardiologist.53 These findings on the timing of ACP agree with
the published literature which cites a change or deterioration in
the patient’s condition, a routine clinical review or a change in
a patient’s personal circumstances such as moving into a care
home as possible triggers for ACP.13
Control patients tended to receive only usual medical prac-
tice but no ACP unless it was specifically requested.52, 54, 56
The majority of studies provided similar amounts of time for
control patients,42, 49–53, 55, 59, 61 for example, through social
calls consisting of conversational topics unrelated to clinical
issues. Therefore, it seems likely that the ACP intervention
and not just time made a difference to clinical outcomes. Two
studies did not provide a clear description on whether an
attempt was made to provide similar amounts of time with
patients and the families of the control groups.57, 58
Characteristics of ACP interventions
Our challenge was to constructively explore existing levels of
heterogeneity and identify intervention components which
may make the use of ACP more effective:
Sidebottom et al.60 attributed the success of their ACP
intervention to using a trained ACP facilitators, educating
patients in communicating their end-of-life care preferences,
involving a family member and offering follow-up appoint-
ments. The literature affirmed the importance of using trained
facilitators and designing multiple ACP components to im-
prove patient outcomes.63–65 Similarly, Wong et al.61 thought
that improvements in their QOL outcomes were due to a
comprehensive palliative care programme including multiple
ACP components: working as a multidisciplinary team, clear
referral guidelines and involvement of carers and patients
alike. Their approach is confirmed by the literature that indi-
cates that ACP is more effective as a complex versus a single
intervention.15, 65, 66
By contrast, Hopp et al.58 used the design of a single
component ACP intervention without any follow-up, involve-
ment of family members or other healthcare professionals.
Additionally, their trial population consisted mainly in African
Americans. Studies have shown that this patient population
prefers curative rather than palliative care approaches and is
less likely to engage with ACP.67, 68 A lack of consideration of
ethnic preferences, missing follow-up and the exclusion of
family members may well have contributed to the low effect
of their ACP intervention. The low effect size for ACP in the
study by Denvir et al.53 was mainly due to the study design,
i.e. a feasibility RCT. The data generated in this small cohort
was not intended to be sensitive or specific enough to observe
a positive effect of the intervention for QOL. Additionally, a
high mortality rate during the follow-up period further limited
the utility of their data as a trial end point.
The study by Detering et al.54 cited five factors for improv-
ing patient satisfaction with end-of-life care1: using trained
facilitators,2 conducting a patient-centred discussion,3 the in-
volvement of the family,4 correctly filing and communicating
the ACP documentation with all parties, and5 a systematic
education of doctors in communicating ACP. Likewise, the
study by Engelhardt et al.56 delivered ACP through trained
care coordinators who had an institutional identity and clinical
credibility. Patients could schedule extra meetings with their
care coordinator if they had further questions and follow-up
was provided. The importance of using respected, senior cli-
nicians to improve the uptake of an intervention like ACP is
highlighted in the literature.69, 70
Lower effect sizes for patient satisfaction with end-of-
life care were found in the study by Brumley et al.52
While the intervention slightly improved outcomes, the
authors thought that a major cause for the low effect
size was the high mortality rate of the study population
before follow-up. Their results suggested that providing
Figure 4 Effect of ACP on quality of communication.
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a multidisciplinary team early in the disease trajectory
of the patient had a small but positive effect on patient
satisfaction with end-of-life care.
Possible causes for the success of the study by Doorenboss
et al.55 corresponded with factors found in other studies of
higher effect sizes: (a) patients were educated by a nurse
through a question prompt list before their appointment with
the cardiologist, (b) the nurse helped patients identifying and
clarifying their care wishes and (c) the clinician was trained in
end-of-life communication skills and had an advanced aware-
ness of the patient’s care preferences.
Lower effect sizes for the quality of end-of-life communica-
tion were reported in the study by Briggs et al.51 Possible causes
for the comparatively small effect might have been similar to
the factors described in the study by Hopp et al.58: ACP was
delivered as a single intervention in the context of a 2-h meet-
ing. Interdisciplinary working with other medical specialties
was missing, and no follow-up was offered to the patient.
Potential Reasons for Over- and Underestima-
tion of Effect
To evaluate potential overestimation of the impact of ACP on
patient outcomes, we carried out subgroup analyses to com-
pare the effect of ACP as a standard intervention versus ACP
as part of a complex palliative care programme. Sufficient data
were only available for quality of end-of-life communication,
and for this outcome, no difference in effect for ACP as a
standard intervention compared to ACP as part of a palliative
care programme was observed. Heterogeneity was
Table 2 Characteristics of ACP Interventions
Study Outcome Effect size
SMD [95%
CI]
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insignificant and confidence intervals of these two subgroups
overlapped substantiating the direction of effect.
The nature of the intervention made it often impossible to
blind participants to the intervention resulting in performance
and selection biases. These factors may have resulted in a
more beneficial effect of ACP compared to standard care since
both patients and physicians may believe that the intervention
works. These biases are a known issue in assessing complex
interventions in palliative care research and need to be con-
sidered when interpreting the reliability and statistical signif-
icance of effect sizes.
Due to the assumptions to make the conversion from SMDs
to ORs, the results are only an approximation. However, the
clinical gain seems sufficiently large to justify the effort of
engaging with ACP in heart failure.
CONCLUSIONS AND CLINICAL IMPLICATIONS
Patients suffering from heart failure have significant palliative
care needs. Only the minority of those dying from heart failure
receives palliative care and their management remains subop-
timal. ACP is widely advocated as a way of addressing these
care needs. But until now, the effect of ACP on heart failure
has not been systematically assessed.
The evidence from this review indicates that ACP
improves the quality of life (SMD, 0.38; 95% CI [0.09
to 0.66]), patient satisfaction with end-of-life care
(SMD, 0.39; 95% CI [0.14 to 0.64]) and the quality of
end-of-life communication (SMD, 0.29; 95% CI [0.17 to
0.42]) for patients suffering from heart failure. Based on
findings from 14 RCTs, we suggest the following con-
siderations to facilitate a better engagement with ACP in
heart failure:
& Introduce ACP at a significant milestone in the patient’s
disease trajectory, for example, after an unscheduled
hospital admission, before hospital discharge or after a
deterioration in the patient’s health status
& Offer follow-up appointments, preferably two or three
meetings or points of contact over a period of time to
allow for the clarification and adjustment of care choices
& Be mindful of ACP preferences
& Offer the involvement of family members or of a health
care proxy
& Work in a multidisciplinary team and not in isolation
within a single medical specialty
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Table 3 Causes of Heterogeneity
Outcome and subgroups Studies Participants Effect size SMD, 95% CI I2
Quality of life (QOL) 7 724 0.38 [0.09 to 0.66] 71%
Patient population
QOL HF patients 6 532 0.39 [0.04 to 0.74] 74%
QOL HF patients + other terminal illnesses 1 192 0.28 [0.00 to 0.57] n/a
Study setting
QOL hospital 3 237 0.18 [− 0.07 to 0.44] 0%
QOL community 1 192 0.28 [0.00 to 0.57] n/a
QOL hospital and community 3 295 0.58 [0.05 to 1.12] 77%
Length of follow-up
QOL F/u to 12 weeks 7 724 0.38 [0.09 to 0.66] 71%
Patient satisfaction with end-of-life care (PSEOLC) 4 1290 0.39 [0.14 to 0.64] 75%
Patient population
PSEOLC HF patients + other terminal illnesses 4 1205 0.39 [0.14 to 0.64] 78%
Study setting
PSEOLC hospital 2 765 0.49 [− 0.03 to 1.01] 92%
PSEOLC community 1 297 0.22 [0.00 to 0.45] n/a
PSEOLC hospital and community11 1 143 0.37 [0.03 to 0.70] n/a
Length of follow-up
PSEOLC F/u to 12 weeks 3 712 0.45 [0.11 to 0.80] 80%
PSEOLC F/u to 24 weeks 1 493 0.23 [0.05 to 0.41] n/a
Quality of end-of-life communication (QEOLC) 4 995 0.29 [0.17 to 0.42] 0%
Patient population
QEOLC HF patients 1 80 0.48 [0.03 to 0.92] n/a
QEOLC HF patients + other terminal illnesses 3 915 0.28 [0.15 to 0.41] 0%
Study setting
QEOLC hospital 4 995 0.29 [0.17 to 0.42] 0%
Length of follow-up
QEOLC F/u to 4 weeks 3 483 0.33 [0.09 to 0.57] 20%
QEOLC F/u to 24 weeks 1 512 0.29 [0.12 to 0.47] n/a
F/u follow-up, HF heart failure, n/a not applicable, PSEOLC Patient Satisfaction with End-of-Life Care, QEOLC quality of end-of-life communication,
QOL quality of life
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